{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:10:25Z","timestamp":1756361425127,"version":"3.44.0"},"reference-count":6,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Review of:<\/jats:bold> Andersson NW, Thomsen SF, Andersen JT. Evaluation of association between oral and topical terbinafine use in pregnancy and risk of major malformations and spontaneous abortion. <jats:italic>JAMA Dermatology<\/jats:italic> 2020;56:375\u2013383<\/jats:p>","DOI":"10.1136\/dtb.2020.000065","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T17:25:31Z","timestamp":1603387531000},"page":"181-181","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of topical and oral terbinafine in pregnancy"],"prefix":"10.1136","volume":"58","member":"239","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"2025082722450557000_58.12.181.1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamadermatol.2020.0142","article-title":"Evaluation of association between oral and topical terbinafine use in pregnancy and risk of major malformations and spontaneous abortion","volume":"156","author":"Andersson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025082722450557000_58.12.181.2","unstructured":"Joint Formulary Committee . British National formulary. Edition 80. London: BMJ Group and Pharmaceutical Press, 2020."},{"key":"2025082722450557000_58.12.181.3","unstructured":"Lamisil Tablets 250mg. Summary of Product Characteristics, UK. Novartis Pharmaceuticals UK Limited, 2020."},{"key":"2025082722450557000_58.12.181.4","unstructured":"Lamisil 1% w\/w Cream. Summary of Product Characteristics, UK. GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 2016."},{"key":"2025082722450557000_58.12.181.5","unstructured":"Sarker MS , RowLand K , Koren G . Pregnancy outcome following gestational exposure to terbinafine: a prospective comparative study [online]. Available: https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.10026 [Accessed 6 October 2020]."},{"key":"2025082722450557000_58.12.181.6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jamadermatol.2019.5036","article-title":"Oral and topical terbinafine for fungal infections in pregnancy","volume":"156","author":"Abel","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2020.000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:45:14Z","timestamp":1756359914000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2020.000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":6,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,11,26]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/dtb.2020.000065"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2020.000065","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2020,10,22]]}}}